TWO DIFFERENT CHARACTERISTICS AND PROGNOSIS OF GRADE 3 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS:
Erciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience
E. Doğan, M. Ozkan, M. Inanc, U. Abdulrezzak, A. Tutuş, F. Ozturk, E. Sozuer, G. Sezgin, S. Gursoy, A. Yurçi, F. Bayram
{"title":"TWO DIFFERENT CHARACTERISTICS AND PROGNOSIS OF GRADE 3 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS:\nErciyes Multidisiplinary Neuroendocrine Tumor (NET) Group Experience","authors":"E. Doğan, M. Ozkan, M. Inanc, U. Abdulrezzak, A. Tutuş, F. Ozturk, E. Sozuer, G. Sezgin, S. Gursoy, A. Yurçi, F. Bayram","doi":"10.5455/annalsmedres.2023.01.017","DOIUrl":null,"url":null,"abstract":"Grade 3 gastroenteropancreatic neuroendocrine tumors (GEPNETs) are not a homogenous group. We aimed to determine clinicopathologic, survival and prognostic differences in metastatic grade 3 GEPNETs with the help of ki67 and GA68PET CT/octreoscan. We divided patients diagnosed metastatic grade 3 GEPNETs into two groups based on the ki67 cut-off point 47 as ki67 low and high. And we divided into 2 groups again according to scan positivity. And we compared all four groups according to clinicopathologic characteristics, survival and prognostic factors. We included 26 patients into our study. The median overall survival in low group was 20 and 10 months in high group (p=0,321). Lower ki67 scan positive group had longer overall survival than lower ki67 scan negative group (NR vs 3 months, respectively, p=0.067) and in high ki67 group the median overall survival was longer in scan positive than negative group (10 vs 9,respectively, p=0.956). The median overall survival was longer in patients with low ki67 levels compared to high ki67 levels. The best overall survival was in low ki67 and scan positive group.","PeriodicalId":8248,"journal":{"name":"Annals of Medical Research","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/annalsmedres.2023.01.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Grade 3 gastroenteropancreatic neuroendocrine tumors (GEPNETs) are not a homogenous group. We aimed to determine clinicopathologic, survival and prognostic differences in metastatic grade 3 GEPNETs with the help of ki67 and GA68PET CT/octreoscan. We divided patients diagnosed metastatic grade 3 GEPNETs into two groups based on the ki67 cut-off point 47 as ki67 low and high. And we divided into 2 groups again according to scan positivity. And we compared all four groups according to clinicopathologic characteristics, survival and prognostic factors. We included 26 patients into our study. The median overall survival in low group was 20 and 10 months in high group (p=0,321). Lower ki67 scan positive group had longer overall survival than lower ki67 scan negative group (NR vs 3 months, respectively, p=0.067) and in high ki67 group the median overall survival was longer in scan positive than negative group (10 vs 9,respectively, p=0.956). The median overall survival was longer in patients with low ki67 levels compared to high ki67 levels. The best overall survival was in low ki67 and scan positive group.